Cambridge Healthtech Institute’s 10th Annual

Clinical Progress of Antibody-Drug Conjugates

Clinical Updates and Lessons Learned

May 7-8, 2020


Today, there are about 80 ADCs in clinical development, with 2 to 3 novel ADCs likely to be approved within the next few years. The clear clinical benefit of ADCs is only overshadowed by its dose-limiting toxicities, but recent improvements in technology combined with clinical data from past ADC programs and related fields are helping to shape the next generation of bioconjugates. At CHI's Clinical Progress of Antibody-Drug Conjugates conference, we invite scientists to share their clinical updates and and lessons learned that can help inform next-generation ADC design and development.

Preliminary Agenda

KEYNOTE PRESENTATION
Key Learnings from Successful and Failed ADCs

Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen

ADVANCES IN THE CLINIC

Combining ADCs and Immunotherapy: Mechanistic Insights and Clinical Observations

Bob Lechleider, PhD, CMO, Seattle Genetics

AVID100: Phase II Tumor Selective Anti-EGFR ADC with Novel Mechanisms of Action

Maureen O'Connor-McCourt, PhD, CSO, Forbius

Are We There Yet?

Anthony Tolcher, PMD, FRCPC, FACP, Director, Clinical Research, CEO & Founder, NEXT Oncology

Belantamab Mafodotin – Driving Innovation for Next-Generation Therapy in Multiple Myeloma

Alex Hoos, MD, PhD, Senior Vice President, Oncology R&D, GlaxoSmithKline Pharmaceuticals

ZW49: Combining Zymeworks' Platforms to Expand the Therapeutic Window of ADCs in HER2-Positive Cancer

Rupert Davies, PhD, Director, Translational Sciences, Zymeworks

Antibody-Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant: Progress toward the Clinic

Charlotte McDonagh, PhD, Vice President, Biotherapeutics, Magenta Therapeutics

PRECLINICAL OUTCOMES AND CLINICAL TRANSLATION

Application of PK/PD M&S for Preclinical-to-Clinical Translation of ADCs

Dhaval K. Shah, PhD, Associate Professor, Pharmaceutical Sciences, University of Buffalo

DAC-002: A Potent Antibody-Drug Conjugate Targeting TROP2-Positive Solid Tumors

Xiaomai Zhou, PhD, Vice President, Biology, Hangzhou DAC BIotech

TAK-164 Preclinical Outcomes

Adnan Abu-Yousif, Takeda

LESSONS LEARNED FROM PAST ADC PROGRAMS AND RELATED FIELDS

A New Mechanism of Malignant Cell Resistance to Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Louis Weiner, MD, Director, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University

Microdistribution of Antibody Distribution in Clinical Trials Using Fluorescently Labeled Anti-EGFR Antibody in Multiple Tumor Types

Eben Rosenthal, MD, Cancer Center Medical Director, Otalaryngology, Stanford University



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated



View By: